Legend Biotech Share Price (NASDAQ: LEGN)

$34.76

▲

0.39

(1.13%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Legend Biotech Stock chart to analyse performance

Legend Biotech stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$34.20
Today's High:$34.76
$34.76
1.63%
Downside
Day's Volatility :1.63%
Upside
0.0%
52 Weeks Low:$27.34
52 Weeks High:$59.62
$34.76
21.35%
Downside
52 Weeks Volatility :54.14%
Upside
41.7%

Legend Biotech Stock Returns

Period	Legend Biotech Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	18.4%	3.6%	0.0%
6 Months	5.26%	-7.7%	0.0%
1 Year	-39.45%	-12.6%	0.0%
3 Years	-25.78%	9.5%	-4.7%

Legend Biotech Corp Key Stats

Check Legend Biotech key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$34.37
Open	$34.46
Today's High	$34.76
Today's Low	$34.195
Market Capitalization	$6.3B
Today's Volume	$881.3K
52 Week High	$59.62
52 Week Low	$27.34
Revenue TTM	$796.8M
EBITDA	$-209.0M
Earnings Per Share (EPS)	$-1.78
Profit Margin	-40.83%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-29.65%

Stock Returns calculator for Legend Biotech Stock including INR - Dollar returns

The Legend Biotech stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Legend Biotech investment value today

Current value as on today

₹65,916

Returns

₹34,084

(-34.08%)

Returns from Legend Biotech Stock

₹39,369 (-39.37%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Legend Biotech Stock

-6%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Legend Biotech Stock from India on INDmoney has decreased by -6% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Legend Biotech Corp

Name
Holdings %
Name
Holdings %
FMR Inc
7.18%
Westfield Capital Management Company, L.P.
3.52%
Hillhouse Capital Advisors, Ltd.
3.25%
BlackRock Inc
2.46%
Suvretta Capital Management, LLC
2.05%
Deerfield Management Co
1.61%

Analyst Recommendation on Legend Biotech Stock

Rating

Trend

Buy

88%Buy

11%Hold

0%Sell

Based on 27 Wall street analysts offering stock ratings for Legend Biotech(by analysts ranked 0 to 5 stars)

Legend Biotech Share Price Target

What analysts predicted

Upside of 122.29%

Target:

$77.27

Current:

$34.76

Legend Biotech share price target is $77.27, a slight Upside of 122.29% compared to current price of $34.76 as per analysts' prediction.

Legend Biotech Stock Insights

Price Movement
In the last 1 month, LEGN stock has moved down by -14.1%
Increasing Revenue
Revenue is up for the last 4 quarters, 160.20M → 255.95M (in $), with an average increase of 14.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 26.28M → -125.82M (in $), with an average decrease of 254.3% per quarter
LEGN vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 109.6%
LEGN vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 134.5%
Price to Sales
ForLEGN every $1 of sales, investors are willing to pay $8.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Legend Biotech Corp Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$57.3M	↑ 16.55%
Net Income	$-133.0M	↑ 4676.29%
Net Profit Margin	-232.21%	↓ 226.54%

	FY20	Y/Y Change
Revenue	$75.7M	↑ 32.15%
Net Income	$-303.5M	↑ 128.23%
Net Profit Margin	-401.02%	↓ 168.81%

	FY21	Y/Y Change
Revenue	$89.8M	↑ 18.65%
Net Income	$-386.2M	↑ 27.26%
Net Profit Margin	-430.12%	↓ 29.1%

	FY22	Y/Y Change
Revenue	$117.0M	↑ 30.31%
Net Income	$-446.3M	↑ 15.57%
Net Profit Margin	-381.48%	↑ 48.64%

	FY23	Y/Y Change
Revenue	$285.1M	↑ 143.7%
Net Income	$-518.3M	↑ 16.11%
Net Profit Margin	-181.75%	↑ 199.73%

	FY24	Y/Y Change
Revenue	$627.2M	↑ 119.97%
Net Income	$-177.0M	↓ 65.84%
Net Profit Margin	-28.22%	↑ 153.53%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$94.0M	↑ 18.28%
Net Income	$-59.8M	↓ 58.71%
Net Profit Margin	-63.62%	↑ 118.62%

	Q2 FY24	Q/Q Change
Revenue	$186.5M	↑ 98.45%
Net Income	$-18.2M	↓ 69.57%
Net Profit Margin	-9.76%	↑ 53.86%

	Q3 FY24	Q/Q Change
Revenue	$160.2M	↓ 14.11%
Net Income	$-125.3M	↑ 588.73%
Net Profit Margin	-78.23%	↓ 68.47%

	Q4 FY24	Q/Q Change
Revenue	$186.5M	↑ 16.43%
Net Income	$26.3M	↓ 120.97%
Net Profit Margin	14.09%	↑ 92.32%

	Q1 FY25	Q/Q Change
Revenue	$195.1M	↑ 4.57%
Net Income	$-100.9M	↓ 483.94%
Net Profit Margin	-51.74%	↓ 65.83%

	Q2 FY25	Q/Q Change
Revenue	$256.0M	↑ 31.22%
Net Income	$-125.8M	↑ 24.68%
Net Profit Margin	-49.16%	↑ 2.58%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$57.3M	↑ 16.55%

	FY20	Y/Y Change
Profit	$-156.5M	↓ 373.27%

	FY21	Y/Y Change
Profit	$-223.6M	↑ 42.86%

	FY22	Y/Y Change
Profit	$51.6M	↓ 123.1%

	FY23	Y/Y Change
Profit	$140.9M	↑ 172.9%

	FY24	Y/Y Change
Profit	$392.7M	↑ 178.62%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$33.5M	↓ 19.52%

	Q2 FY24	Q/Q Change
Profit	$136.1M	↑ 305.82%

	Q3 FY24	Q/Q Change
Profit	$104.7M	↓ 23.03%

	Q4 FY24	Q/Q Change
Profit	$112.6M	↑ 7.51%

	Q1 FY25	Q/Q Change
Profit	$123.7M	↑ 9.87%

	Q2 FY25	Q/Q Change
Profit	$151.7M	↑ 22.66%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-83.1M	↓ 127.0%
Investing Cash Flow	$-58.7M	↓ 42.64%
Financing Cash Flow	$14.7M	↑ 486.41%

	FY20	Y/Y Change
Operating Cash Flow	$-223.0M	↑ 168.47%
Investing Cash Flow	$-24.2M	↓ 58.79%
Financing Cash Flow	$618.9M	↑ 4119.82%

	FY21	Y/Y Change
Operating Cash Flow	$-198.5M	↓ 11.0%
Investing Cash Flow	$-195.0M	↑ 706.75%
Financing Cash Flow	$626.7M	↑ 1.26%

	FY22	Y/Y Change
Operating Cash Flow	$-200.0M	↑ 0.79%
Investing Cash Flow	$-78.3M	↓ 59.82%
Financing Cash Flow	$378.0M	↓ 39.68%

	FY23	Y/Y Change
Operating Cash Flow	$-393.3M	↑ 96.61%
Investing Cash Flow	$92.8M	↓ 218.43%
Financing Cash Flow	$791.5M	↑ 109.4%

	FY24	Y/Y Change
Operating Cash Flow	$-144.0M	↓ 63.38%
Investing Cash Flow	$-850.5M	↓ 1016.67%
Financing Cash Flow	$5.7M	↓ 99.28%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$16.2M	↓ 117.35%
Investing Cash Flow	$-396.8M	↓ 197.95%
Financing Cash Flow	$831.0K	↓ 10.16%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-1.7M	↓ 110.2%
Investing Cash Flow	$-695.6M	↑ 75.31%
Financing Cash Flow	$955.0K	↑ 14.92%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-75.8M	↑ 4492.49%
Investing Cash Flow	$329.1M	↓ 147.31%
Financing Cash Flow	$4.2M	↑ 344.5%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-82.1M	↑ 8.25%
Investing Cash Flow	$-87.8M	↓ 126.69%
Financing Cash Flow	$-333.0K	↓ 107.84%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-103.8M	↑ 26.41%
Investing Cash Flow	$256.6M	↓ 392.16%
Financing Cash Flow	$667.0K	↓ 300.3%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-13.0M	↓ 87.43%
Investing Cash Flow	$-165.5M	↓ 164.5%
Financing Cash Flow	$-990.0K	↓ 248.43%

Legend Biotech Technicals Summary

Sell

Neutral

Buy

Legend Biotech is currently in a neutral trading position according to technical analysis indicators.

Legend Biotech Corp Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Legend Biotech Corp	-10.53%	5.26%	-39.45%	-25.78%	6.26%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Legend Biotech Corp	NA	NA	NA	-0.75	-0.3	-0.08	NA	5.61
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Legend Biotech Corp	Buy	$6.3B	6.26%	NA	-40.83%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

Legend Biotech Dividend announcements

Legend Biotech Earnings
Legend Biotech’s price-to-earnings ratio stands at None

About Legend Biotech Corp

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey.

Organization	Legend Biotech
Employees	2800
CEO	Dr. Ying Huang Ph.D.
Industry	Commercial Services

Key Management of Legend Biotech Corp

Name	Title
Dr. Ying Huang Ph.D.	CEO & Director
Mr. Carlos Santos	Chief Financial Officer

Important FAQs about investing in LEGN Stock from India :

What is Legend Biotech share price today?

Legend Biotech share price today is $34.76 as on August 30, 2025 at 1:29 am IST at the close of the market. Legend Biotech share today touched a day high of $34.76 and a low of $34.20.

What is the 52 week high and 52 week low for Legend Biotech share?

Legend Biotech share touched a 52 week high of $59.62 and a 52 week low of $27.34. Legend Biotech stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $34.76, lower by 41.7% versus the 52 week high.

How to invest in Legend Biotech Stock (LEGN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Legend Biotech on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Legend Biotech Shares that will get you 0.0432 shares as per Legend Biotech share price of $34.76 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Legend Biotech Stock (LEGN) from India?

Indian investors can start investing in Legend Biotech (LEGN) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Legend Biotech stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Legend Biotech share’s latest price of $34.76 as on August 30, 2025 at 1:29 am IST, you will get 0.2877 shares of Legend Biotech. Learn more about fractional shares .

What are the returns that Legend Biotech has given to Indian investors in the last 5 years?

Legend Biotech stock has given 6.26% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?